Issue Date: February 29, 2016
Immunotherapy firm Forty Seven launches
Cancer-immunotherapy-focused Forty Seven has launched with $75 million in its first round of financing. Forty Seven has licensed the rights to patents covering Hu5F9-G4, a humanized monoclonal antibody against CD47, and other immuno-oncology targets and antibodies. Three Stanford University researchers identified CD47 as an attractive cancer target in 2009 and have since put Hu5F9-G4 into two Phase I studies in people with acute myeloid leukemia or solid tumors.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society